Student Group

Polycythemia vera (PV), a rare blood cancer characterized by the overproduction of red blood cells, has traditionally been managed with therapeutic phlebotomy and cytoreductive agents such as hydroxyurea. However, 2025 marks a pivotal moment in the evolution of PV treatment, as advances in targeted therapies are fundamentally transforming the clinical landscape. These novel approaches are not only enhancing disease control and improving patient outcomes, but also addressing the molecular drivers of the disease, offering hope for more personalized and durable treatments.

Understanding Polycythemia Vera and Its Challenges

Polycythemia vera   is classified as a myeloproliferative neoplasm (MPN), a group of disorders that result in the excessive production of blood cells. The disease is largely driven by a mutation in the Janus kinase 2 (JAK2) gene—specifically, the V617F mutation, which is present in approximately 95% of PV patients. This mutation leads to continuous activation of the JAK-STAT signaling pathway, promoting abnormal cell growth…

COVID-19 crisis has affected the supply and demand of products, although for a short term. Investors are skeptical whether the upsurge in product spending will alter or remain the same. Regardless of some disturbances caused by COVID-19 lockdown measures across the globe, the long-term growth potential of the sector remains unharmed. The current situation of lockdown in several countries is driving the demand for car covers, as people have no option but to park their cars outside. The cars are already unfunctional. Hence car covers help them from the further damage that can be caused by many external factors such as dust, dirt, UV rays, rains, snow, and birds falling.

In 2023, the car covers market size was estimated to be worth USD 0.8 billion. According to projections, the car covers industry would expand at a compound annual growth rate (CAGR) of 2.95% from 2024 to 2032, from USD 0.9…